@Wasabibarako Look at the broader stem cell sector for your answers and CYP's inertia. Plenty of comparable US companies have faced even larger sell downs. CYP needs some good news on trials or other developments. Its simply the nature of speculative bio tech, the share prices often behave like decaying call options in effect. I do think you just saw a lot of end of US year tax selling on the biggest yearly SP500 decline since 2008. You may see a bounce in small caps (Russell Index in US) and bio-techs within that. An MSB resubmission soon might buoy the sector.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)